Fresenius SE & Co. KGaA

  • WKN: 578560
  • ISIN: DE0005785604
  • Land: Deutschland

Nachricht vom 28.06.2021 | 16:33

DGAP-DD: Fresenius SE & Co. KGaA english

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
28.06.2021 / 16:33
The issuer is solely responsible for the content of this announcement.

1. Details of the person discharging managerial responsibilities / person closely associated

a) Name
Title: Dr.
First name: Ernst
Last name(s): Wastler

2. Reason for the notification

a) Position / status
Position: Member of the managing body

b) Initial notification

3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name
Fresenius SE & Co. KGaA

b) LEI

4. Details of the transaction(s)

a) Description of the financial instrument, type of instrument, identification code
Type: Share
ISIN: DE0005785604

b) Nature of the transaction
Exercise of options on Fresenius shares of the stock option plan and sale of the shares (cash settlement)
Transaction linked to the exercise of share option programmes

c) Price(s) and volume(s)
Price(s) Volume(s)
44 EUR 19008 EUR
44 EUR 717420 EUR
44 EUR 17072 EUR
44 EUR 27060 EUR
44 EUR 33000 EUR
44 EUR 20196 EUR
44 EUR 359700 EUR
44 EUR 97548 EUR
44 EUR 66440 EUR
44 EUR 80520 EUR
44 EUR 100012 EUR
44 EUR 83072 EUR
44 EUR 70048 EUR
44 EUR 8800 EUR
44 EUR 91652 EUR
44 EUR 44000 EUR
44 EUR 11000 EUR
44 EUR 79332 EUR
44 EUR 17072 EUR
44 EUR 11000 EUR
44 EUR 26048 EUR

d) Aggregated information
Price Aggregated volume
44.0000 EUR 1980000.0000 EUR

e) Date of the transaction
2021-06-25; UTC+2

f) Place of the transaction
Name: Xetra

28.06.2021 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

Aktuelle Research-Studie

Original-Research: Gold Mountain Mining Corp. (von hanseatic stock publishing UG (haftungsbeschränkt)): Gold Mountain Mining Corp.

29. November 2021